AnorMED About
AnorMED: AnorMED is a chemistry-based biopharmaceutical
company focused on the discovery, development and commercialization of new therapeutic
products in the areas of hemotology, HIV and oncology. AnorMED's core strength
involves the application of chemistry, biochemistry and biology to the discover
and development of small molecule therapeutics with distinct pharmocological properties
and therapeutic potential. AMD3100, a
stem cell mobilizer AMD070 --HIV Inhibitor is a small
molecule drug candidate that belongs to a new investigational class of anti-HIV
drugs known as entry inhibitors. AMD070 targets the CXCR4 chemokine receptor and
prevents HIV from entering and infecting healthy cells.
More on AnorMed: